HPV vaccine
Why in News?
The Human Papillomavirus (HPV) vaccine is recently in the news due to two landmark healthcare breakthroughs: the World Health Organization (WHO) prequalification of India's indigenous vaccine CERVAVAC, and a massive global clinical study showing that the vaccine prevents major pregnancy complications.
What is the HPV Vaccine?
- The Target Virus: The vaccine protects against the Human Papillomavirus (HPV), an incredibly common sexually transmitted infection.
- Cancer Prevention: Persistent infection with high-risk HPV strains causes 95% of cervical cancers, alongside other malignancies such as penile, anal, vaginal, and throat cancers.
- How it Works: The vaccine uses non-infectious, virus-like particles to trigger the immune system into producing antibodies, offering 93% to 100% lifetime efficacy against the targeted strains.
Types of Vaccines & Global Availability
- CERVAVAC: India’s first indigenously developed, gender-neutral quadrivalent vaccine targeting HPV types 6, 11, 16, and 18. It is approved for both boys and girls aged 9 to 26.
- Gardasil & Gardasil 9: Manufactured by Merck, these are widely used quadrivalent and nonavalent vaccines. Gardasil 9 covers 9 different HPV strains, providing the broadest spectrum of protection.
- Cervarix: A bivalent vaccine focused primarily on strains 16 and 18, which cause 70% of all cervical cancers.
Dosage, Age Guidelines, & Public Health Programs
- Prime Target Age: The vaccine is most effective when administered between 9 and 14 years of age before any exposure to the virus.
- Dosage Schedules: The WHO recommends a single-dose or two-dose schedule for young adolescents to optimize public health coverage and affordability. A three-dose schedule is typically reserved for individuals vaccinated later in life (ages 15–26) or those who are immunocompromised.
- National Immunization Drives: India launched a massive nationwide campaign providing free single-dose Gardasil vaccinations to 1.15 crore (11.5 million) 14-year-old girls. This initiative aims to tackle the heavy disease burden, as India historically accounts for 25% of global cervical cancer deaths.
Safety & Long-term Efficacy
- Extensively Proven: More than 500 million doses have been administered worldwide since 2006 under rigorous surveillance.
- Side Effects: The vaccine has a reassuring safety profile. Minor side effects are limited to temporary injection site soreness, mild fever, or brief dizziness (syncope) immediately following administration.
- Duration: Studies confirm robust, active protection lasting at least 5 to 10 years, with mathematical models projecting lifelong immune memory.
